Keay Nakae Analyst PerformanceSenior Research Analyst, Small RNA, Microbiome, Digital Therapeutics at Chardan CapitalKeay Nakae is a stock analyst at Chardan Capital focused in the healthcare sector, covering 38 publicly traded companies. Over the past year, Keay Nakae has issued 66 stock ratings, including buy and hold recommendations. While full access to Keay Nakae's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Keay Nakae's coverage history, rating activity, and performance tendencies - helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings187 Last 10 YearsBuy Recommendations92.39% 170 Buy RatingsCompanies Covered38 Unique Companies Ratings Distribution184RatingsDistribution of strong buy, buy, hold, and sell ratings by Keay Nakae.RatingPercentageCount Strong Buy0.0%0 ratings Buy92.4%170 ratings Hold7.1%12 ratings Sell0.5%1 ratingsOut of 184 total stock ratings issued by Keay Nakae at Chardan Capital, the majority (92.4%) have been Buy recommendations, followed by 7.1% Hold and 0.5% Sell.Best & Worst CallsBest Call000000.0%OCGNJun 2020Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call0000.0%KLDONov 2021Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ89.5% of companies on NASDAQ34 companiesNYSE7.9% of companies on NYSE3 companiesNYSEAMERICAN2.6% of companies on NYSEAMERICAN1 companyKeay Nakae, an analyst at Chardan Capital, currently covers 38 companies listed on NASDAQ, NYSE and NYSEAMERICAN, with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageHealthcare35 companies92.1%Technology2 companies5.3%Miscellaneous1 company2.6%Keay Nakae of Chardan Capital specializes in stock coverage within the Healthcare sector, with additional focus on Technology and companies.Coverage IndustriesIndustryPercentageBIOTECHNOLOGY28 companies73.7%PHARMACEUTICALS3 companies7.9%HEALTHCARE EQUIPMENT & SUPPLIES3 companies7.9%SOFTWARE2 companies5.3%BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC1 company2.6%Miscellaneous1 company2.6% About Keay NakaeKeay Nakae is a Senior Research Analyst at Chardan. Mr. Nakae has over 17 years of experience as a sell-side research analyst covering healthcare companies, and has previously worked at Wedbush Morgan, and CE Unterberg Towbin/Collins Stewart. Mr. Nakae has made numerous media appearances on Bloomberg TV, and has been quoted in publications such as The Wall Street Journal, Time, Business Week, and The Los Angeles Times. He has been recognized by Forbes magazine in its annual survey of America’s Best Analysts. Mr. Nakae earned an MBA degree from UCLA’s Anderson School of Management, and holds MS and BS degrees in electronic engineering from Cal Poly. Mr. Nakae is a CFA charterholder and a member of the CFA Institute.Follow on LinkedIn Keay Nakae's Ratings History at Chardan Capital Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsSTOKStoke Therapeutics8/4/2026Reiterated Rating$29.56$35.00Buy$0.0000.00% ROIALNYAlnylam Pharmaceuticals7/31/2026Reiterated Rating$205.48$425.00Buy$0.0000.00% ROIPMNPromis Neurosciences7/27/2026Set Price Target$12.20$20.00Buy$0.0000.00% ROIPMNPromis Neurosciences7/27/2026Initiated Coverage$14.52$20.00Buy$0.0000.00% ROIARWRArrowhead Pharmaceuticals7/22/2026Boost Price Target$89.36$115.00Buy$0.0000.00% ROIMGXMetagenomi7/7/2026Initiated Coverage$1.25$5.00Buy$0.0000.00% ROIIBIOiBio7/2/2026Reiterated Rating$1.75$5.00Buy$0.0000.00% ROIARWRArrowhead Pharmaceuticals6/30/2026Reiterated Rating$80.50$90.00Buy$0.0000.00% ROIPRQRProQR Therapeutics6/26/2026Lower Price Target$1.57$3.00Buy$0.0000.00% ROISABSSAB Biotherapeutics6/17/2026Boost Price Target$3.66$16.00Buy$0.0000.00% ROI Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. COYACoya Therapeutics6/12/2026Reiterated Rating$4.89$14.00Buy$0.0000.00% ROICAMPCAMP4 Therapeutics6/10/2026Set Price Target$4.01$6.50Buy$0.0000.00% ROICAMPCAMP4 Therapeutics6/10/2026Initiated Coverage$4.34$6.50Buy$0.0000.00% ROIANROAlto Neuroscience4/22/2026Reiterated Rating$27.13$30.00Buy$0.0000.00% ROIPRQRProQR Therapeutics4/9/2026Reiterated Rating$1.83$4.00Buy$0.0000.00% ROIIBIOiBio4/9/2026Reiterated Rating$2.24$5.00Buy$0.0000.00% ROIANROAlto Neuroscience4/2/2026Reiterated Rating$23.38$30.00Buy$0.0000.00% ROIMNPRMonopar Therapeutics3/30/2026Reiterated Rating$54.10$100.00Buy$0.0000.00% ROIALNYAlnylam Pharmaceuticals3/25/2026Reiterated Rating$326.30$425.00Buy$0.0000.00% ROIIBIOiBio3/18/2026Reiterated Rating$2.46$5.00Buy$0.0000.00% ROISTOKStoke Therapeutics3/18/2026Reiterated Rating$32.87$35.00Buy$0.0000.00% ROIANROAlto Neuroscience3/17/2026Reiterated Rating$24.27$30.00Buy$0.0000.00% ROICOYACoya Therapeutics3/16/2026Reiterated Rating$4.47$14.00Buy$0.0000.00% ROIOBIOOrchestra BioMed3/12/2026Reiterated Rating$4.38$20.00Buy$0.0000.00% ROISABSSAB Biotherapeutics3/11/2026Boost Price Target$4.54$14.00Buy$0.0000.00% ROIDYNDyne Therapeutics3/9/2026Reiterated Rating$17.64$38.00Buy$0.0000.00% ROIDYNDyne Therapeutics3/2/2026Reiterated Rating$16.15$38.00Buy$0.0000.00% ROIALURAllurion Technologies2/24/2026Set Price Target$26.21$45.00Buy$0.0000.00% ROIALURAllurion Technologies2/24/2026Set Price Target$18.23$45.00$0.0000.00% ROIALNYAlnylam Pharmaceuticals2/13/2026Lower Price Target$308.48$425.00Buy$0.0000.00% ROIIBIOiBio2/12/2026Reiterated Rating$2.21$5.00Buy$0.0000.00% ROIKRROKorro Bio1/29/2026Upgrade$11.69$15.00Buy$0.0000.00% ROIMNPRMonopar Therapeutics1/29/2026Reiterated Rating$67.43$100.00Buy$0.0000.00% ROICOYACoya Therapeutics1/8/2026Reiterated Rating$5.12$14.00Buy$0.0000.00% ROIARWRArrowhead Pharmaceuticals1/7/2026Boost Price Target$70.81$80.00Buy$0.0000.00% ROISTOKStoke Therapeutics1/5/2026Set Price Target$30.90$35.00$0.0000.00% ROIRVPHReviva Pharmaceuticals1/5/2026Reiterated Rating$6.20$40.00Buy$0.0000.00% ROISTOKStoke Therapeutics1/5/2026Boost Price Target$30.90$35.00Buy$0.0000.00% ROIANROAlto Neuroscience1/5/2026Boost Price Target$16.61$30.00Buy$0.0000.00% ROISABSSAB Biotherapeutics12/18/2025Reiterated Rating$3.96$12.00Buy$0.0000.00% ROIYour $29.97 book is free today (Ad)Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options can give you up to 12 times the leverage of stocks — with a fraction of the capital tied up. This free guide lays it all out in plain English — from A to Z, with step-by-step examples you can follow in your own account.Normally $29.97. Today it's free. Grab your copy now.DYNDyne Therapeutics12/9/2025Reiterated Rating$22.20$38.00Buy$0.0000.00% ROIARWRArrowhead Pharmaceuticals12/1/2025Reiterated Rating$52.78$60.00Buy$0.0000.00% ROIALURAllurion Technologies11/20/2025Reiterated Rating$1.35Neutral$0.0000.00% ROIARWRArrowhead Pharmaceuticals11/19/2025Reiterated Rating$40.47$60.00Buy$0.0000.00% ROISABSSAB Biotherapeutics11/17/2025Reiterated Rating$3.24$12.00Buy$0.0000.00% ROICOYACoya Therapeutics11/14/2025Reiterated Rating$5.96$14.00Buy$0.0000.00% ROIABUSArbutus Biopharma11/14/2025Reiterated Rating$4.52$5.00Buy$0.0000.00% ROIKRROKorro Bio11/13/2025Reiterated Rating$31.42Neutral$0.0000.00% ROIOBIOOrchestra BioMed11/13/2025Reiterated Rating$4.42$20.00Buy$0.0000.00% ROIRNAAvidity Biosciences11/11/2025Reiterated Rating$69.84$72.00Neutral$0.0000.00% ROIMNPRMonopar Therapeutics11/9/2025Boost Price Target$80.95$100.00Buy$0.0000.00% ROIPRQRProQR Therapeutics11/4/2025Reiterated Rating$2.59$4.00Buy$0.0000.00% ROIRNAAvidity Biosciences10/28/2025Reiterated Rating$70.00$72.00Neutral$0.0000.00% ROIRNAAvidity Biosciences10/28/2025Set Price Target$70.00$72.00$0.0000.00% ROIRNAAvidity Biosciences10/28/2025Downgrade$69.93$72.00Hold$0.0000.00% ROIMNPRMonopar Therapeutics9/25/2025Boost Price Target$73.04$85.00Buy$0.0000.00% ROISABSSAB Biotherapeutics9/19/2025Reiterated Rating$2.38$12.00Buy$0.0000.00% ROICOYACoya Therapeutics9/17/2025Reiterated Rating$5.67$14.00Buy$0.0000.00% ROIMNPRMonopar Therapeutics9/16/2025Reiterated Rating$54.49$60.00Buy$0.0000.00% ROIRNAAvidity Biosciences9/10/2025Reiterated Rating$47.34$75.00Buy$0.0000.00% ROICOYACoya Therapeutics8/13/2025Reiterated Rating$6.02$14.00Buy$0.0000.00% ROIKRROKorro Bio8/13/2025Reiterated Rating$18.93$25.00Buy$0.0000.00% ROIMNPRMonopar Therapeutics8/13/2025Reiterated Rating$33.51$60.00Buy$0.0000.00% ROIOBIOOrchestra BioMed8/13/2025Reiterated Rating$2.66$20.00Buy$0.0000.00% ROIARWRArrowhead Pharmaceuticals8/11/2025Reiterated Rating$16.42$60.00Buy$0.0000.00% ROIABUSArbutus Biopharma8/11/2025Reiterated Rating$3.40$5.00Buy$0.0000.00% ROISABSSAB Biotherapeutics8/8/2025Lower Price Target$2.23$12.00Buy$0.0000.00% ROISLNSilence Therapeutics8/8/2025Reiterated Rating$5.38$35.00Buy$0.0000.00% ROIPRQRProQR Therapeutics8/8/2025Reiterated Rating$2.05$4.00Buy$0.0000.00% ROIRNAAvidity Biosciences8/8/2025Reiterated Rating$47.52$75.00Buy$0.0000.00% ROIOBIOOrchestra BioMed8/7/2025Reiterated Rating$2.64$20.00Buy$0.0000.00% ROIALNYAlnylam Pharmaceuticals8/1/2025Boost Price Target$392.24$400.00Buy$000.0000.00% ROIDYNDyne Therapeutics7/29/2025Lower Price Target$9.31$38.00Buy$00.0000.00% ROICOYACoya Therapeutics7/1/2025Reiterated Rating$5.72$14.00Buy$0.0000.00% ROIIBIOiBio6/25/2025Reiterated Rating$0.75$5.00Buy$0.0000.00% ROIMNPRMonopar Therapeutics6/23/2025Initiated Coverage$32.86$60.00Buy$00.0000.00% ROIDYNDyne Therapeutics6/17/2025Reiterated Rating$11.48$50.00Buy$00.0000.00% ROISLNSilence Therapeutics6/13/2025Reiterated Rating$5.59$35.00Buy$0.0000.00% ROIRNAAvidity Biosciences6/9/2025Boost Price Target$33.13$75.00Buy$00.0000.00% ROISABSSAB Biotherapeutics5/15/2025Reiterated Rating$2.01$20.00Buy$0.0000.00% ROIARWRArrowhead Pharmaceuticals5/13/2025Reiterated Rating$13.97$60.00Buy$00.0000.00% ROIOBIOOrchestra BioMed5/13/2025Reiterated Rating$2.94$20.00Buy$0.0000.00% ROICOYACoya Therapeutics5/13/2025Reiterated Rating$5.76$14.00Buy$0.0000.00% ROIDYNDyne Therapeutics5/9/2025Reiterated Rating$11.32$50.00Buy$00.0000.00% ROISLNSilence Therapeutics5/9/2025Lower Price Target$3.56$35.00Buy$0.0000.00% ROIMCRBSeres Therapeutics5/8/2025Reiterated Rating$8.29$6.00Neutral$0.0000.00% ROIRNAAvidity Biosciences5/7/2025Reiterated Rating$26.26$65.00Buy$00.0000.00% ROIIBIOiBio5/5/2025Reiterated Rating$1.01$5.00Buy$0.0000.00% ROIALNYAlnylam Pharmaceuticals5/2/2025Boost Price Target$255.13$325.00Buy$000.0000.00% ROICOYACoya Therapeutics4/28/2025Reiterated Rating$6.18$14.00Buy$0.0000.00% ROIThe $15 Gold Fund That Pays Up to $1,152/Month (Ad)Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required. Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away.Discover the gold income fund before the next payout dateOBIOOrchestra BioMed4/22/2025Reiterated Rating$2.90$20.00Buy$0.0000.00% ROIKRROKorro Bio4/16/2025Initiated Coverage$13.40$25.00Buy$00.0000.00% ROISONNSonnet BioTherapeutics4/7/2025Reiterated Rating$1.25$20.00Buy$0.0000.00% ROISABSSAB Biotherapeutics4/1/2025Lower Price Target$1.40$20.00Buy$0.0000.00% ROIOBIOOrchestra BioMed4/1/2025Reiterated Rating$3.24$20.00Buy$0.0000.00% ROIGANXGain Therapeutics3/28/2025Reiterated Rating$2.07$6.00Buy$0.0000.00% ROIABUSArbutus Biopharma3/28/2025Reiterated Rating$3.27$5.00Buy$0.0000.00% ROISONNSonnet BioTherapeutics3/28/2025Reiterated Rating$1.31$20.00Buy$0.0000.00% ROIALNYAlnylam Pharmaceuticals3/21/2025Reiterated Rating$253.60$300.00Buy$000.0000.00% ROICOYACoya Therapeutics3/20/2025Reiterated Rating$6.45$14.00Buy$0.0000.00% ROIMCRBSeres Therapeutics3/20/2025Reiterated Rating$14.64$25.00Buy$0.0000.00% ROIDYNDyne Therapeutics3/17/2025Reiterated Rating$12.22$50.00Buy$00.0000.00% ROIPRQRProQR Therapeutics3/14/2025Reiterated Rating$1.74$4.00Buy$0.0000.00% ROIDYNDyne Therapeutics2/28/2025Reiterated Rating$13.30$50.00Buy$00.0000.00% ROIALNYAlnylam Pharmaceuticals2/26/2025Reiterated Rating$245.20$300.00Buy$000.0000.00% ROIARWRArrowhead Pharmaceuticals2/11/2025Reiterated Rating$19.92$60.00Buy$00.0000.00% ROICOYACoya Therapeutics2/6/2025Reiterated Rating$7.00$14.00Buy$0.0000.00% ROISABSSAB Biotherapeutics1/29/2025Reiterated Rating$2.28$25.00Buy$0.0000.00% ROIDYNDyne Therapeutics1/10/2025Reiterated Rating$15.46$50.00Buy$00.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageWall Street ZenBarclaysRoyal Bank Of CanadaMorgan StanleyJefferies Financial GroupThe Goldman Sachs GroupBMO Capital MarketsSanford C. BernsteinBerenberg BankBNP Paribas ExaneCompass PointPiper SandlerCanadian Imperial Bank of CommerceWeiss RatingsUBS Group Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
